

promptly-reported post-donation information, we will continue to monitor and assess our biological

product deviation reporting program and make adjustments accordingly.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN¹

21 CFR Section	Form No.	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
600.14	3,486	115	4.1	476	2	952
606.171 ²	3,486	207	130.4	27,000	2	54,000
606.171 ³	3,486	6,021	1.1	6,446	2	12,892
Total						67,844

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

² Licensed manufacturers of human blood and blood components, including Source Plasma.

³ Unlicensed registered blood establishments and transfusion services (2,800 + 3,221 = 6,021).

Dated: December 16, 2003.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. 03-32160 Filed 12-30-03; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Tentative Schedule of Meetings for 2004

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2004. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (IOM) conducted a

study of the use of FDA's advisory committees. In its final report, one of IOM's recommendations was for the agency to publish an annual tentative schedule of its meetings in the **Federal Register**. This publication implements IOM's recommendation.

FOR FURTHER INFORMATION CONTACT:

Theresa L. Green, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

SUPPLEMENTARY INFORMATION: IOM, at the request of the Commissioner, undertook a study of the use of FDA's advisory committees. In its final report in 1992, one of IOM's recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**. FDA has implemented this recommendation. The annual publication of tentatively scheduled

advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. Because the schedule is tentative, amendments to this notice will not be published in the **Federal Register**. However, changes to the schedule will be posted on FDA's advisory committees' Internet site located at <http://www.fda.gov/oc/advisory/default.htm>. FDA will continue to publish a **Federal Register** notice 15 days in advance of each upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 2004. You may also obtain up-to-date meeting information by calling the Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area).

Committee Name	Date(s) of Meetings	Advisory Committee 10-Digit Information Line Code
OFFICE OF THE COMMISSIONER		
Science Board to the Food and Drug Administration	April 22, November 4	3014512603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH		
Allergenic Products Advisory Committee	April 2	3014512388
Biological Response Modifiers Advisory Committee	March 18-19, July 15-16, November 18-19	3014512389
Blood Products Advisory Committee	March 18-19, July 12-13, October 21-22	3014519516
Transmissible Spongiform Encephalopathies Advisory Committee	February 12-13, June 29-30, October 14-15	3014512392